You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萬泰生物計劃10月開展鼻噴流感病毒載體新冠肺炎疫苗Ⅲ期臨牀試驗
格隆匯 09-23 15:20
格隆匯9月23日丨中國臨牀試驗註冊中心記錄顯示,中國疫苗研發企業北京萬泰生物(603392.SH)計劃於10月開展鼻噴流感病毒載體新冠肺炎疫苗Ⅲ期臨牀試驗。該記錄並顯示,在Ⅲ期臨牀試驗中,其計劃招募4000名成年參與者;其中2000名在兩週內接種試驗疫苗;另外2000名則接種安慰劑對照疫苗。上述記錄並未顯示萬泰將在多少個國家進行該臨牀試驗,但稱菲律賓信號聯合研究倫理委員會已批准了該項研究,為可能在該國進行試驗掃清障礙。一位萬泰生物人士稱,該項臨牀試驗註冊記錄並不意味着該公司已經正式啟動Ⅲ期臨牀試驗,其仍在等待監管當局進一步文件,但並未説明這些文件將來自哪些國家監管機構。作為常見的手臂注射的替代方案,鼻腔噴霧疫苗可以通過模擬呼吸道病毒天然感染途徑,激活局部免疫應答和全身性免疫應答,發揮保護作用。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account